Mata Marina, Hao Shuanglin, Fink David J
Department of Neurology, University of Michigan School of Medicine and VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Curr Gene Ther. 2008 Feb;8(1):42-8. doi: 10.2174/156652308783688527.
Chronic pain is a highly prevalent condition that impacts adversely on individual quality of life, imposes substantial costs on the healthcare system and a considerable burden on society. Advances in the understanding of pain mechanisms have opened the way for the development of new treatment strategies. The continuous delivery of short-lived potent bioactive molecules to sensory nerves, spinal cord or meninges--achieved by directed gene transfer--offers the possibility to selectively interrupt nociceptive neurotransmission or to interfere with the plastic changes in the nervous system underlying the development or persistence of chronic pain. In this review we describe advances in the use of non-viral and viral vector-based gene transfer for the treatment of pain, with a special focus on the use of recombinant non-replicating herpes simplex virus-based vectors and the prospects for clinical trials.
慢性疼痛是一种非常普遍的病症，对个人生活质量产生不利影响，给医疗系统带来巨大成本，并给社会造成相当大的负担。对疼痛机制理解的进展为新治疗策略的开发开辟了道路。通过定向基因转移实现向感觉神经、脊髓或脑膜持续递送短效强效生物活性分子，为选择性中断伤害性神经传递或干扰慢性疼痛发生或持续的神经系统可塑性变化提供了可能性。在本综述中，我们描述了使用基于非病毒和病毒载体的基因转移治疗疼痛方面的进展，特别关注基于重组非复制型单纯疱疹病毒载体的使用以及临床试验前景。
